公开(公告)号：US20240105992A1

公开(公告)日：2024-03-28

申请号：US18273674

申请日：2022-01-14

Applicant: Central Glass Company, Limited

Inventor： Ryosuke TERADA ,  Masahiro MIURA ,  Takayoshi MORINAKA ,  Mikihiro TAKAHASHI

IPC: H01M10/0567 ,  C07D233/34 ,  C07F9/6506 ,  H01M10/0569

CPC classification number: H01M10/0567 ,  C07D233/34 ,  C07F9/6506 ,  H01M10/0569 ,  H01M2300/0034 ,  H01M2300/0042

Abstract: According to a nonaqueous electrolytic solution containing: a compound represented by General Formula (1); a solute; and a nonaqueous organic solvent, a nonaqueous electrolytic solution battery, and a compound represented by the General Formula (1), a nonaqueous electrolytic solution and a nonaqueous electrolytic solution battery having a low initial resistance value, and a compound that can be suitably used for the above nonaqueous electrolytic solution are provided.

公开(公告)号：US20220098157A1

公开(公告)日：2022-03-31

申请号：US17310498

申请日：2020-02-04

Applicant: NOURYON CHEMICALS INTERNATIONAL B.V.

Inventor： Ina EHLERS ,  Eike Nicolas KANTZER ,  Rolf Krister EDVINSSON ,  Karl Fredrik LAKE ,  Hendrik VAN DAM ,  Antoon Jacob Berend TEN KATE ,  Michiel Jozef Thomas RAAIJMAKERS ,  Rens VENEMAN ,  Slavisa JOVIC ,  Lawien Feisal ZUBEIR

IPC: C07D233/34 ,  C09K15/30 ,  C23F11/14

Abstract: A compound comprises at least one cyclic urea moiety including a head portion and a tail portion connected through an amide moiety or a cyclic amidine moiety, wherein the head portion comprises a polyalkylenepolyamine structure comprising 3 to 10 C2-C4 alkylene moieties present between nitrogen atoms, wherein the alkylene moieties may be the same or different and may be substituted with one or more C1 to C3 alkyl groups, wherein at least one of the alkylene moieties together with its adjoining nitrogen atoms is in the form of a cyclic alkylene urea moiety of the formula wherein A is a C2 to C4 alkylene moiety which may be substituted with one or more C1 to C3 alkyl groups and wherein the tail portion includes an alkyl or alkenyl group with 6 to 24 carbon atoms which may be substituted.

公开(公告)号：US20200165207A1

公开(公告)日：2020-05-28

申请号：US16630283

申请日：2018-07-03

Applicant: NOURYON CHEMICALS INTERNATIONAL B.V.

Inventor： Eike Nicolas KANTZER ,  Karl Fredrik LAKE ,  Antoon Jacob Berend TEN KATE ,  Michiel Jozef Thomas RAAIJMAKERS ,  Rens VENEMAN ,  Rolf Krister EDVINSSON ,  Ina EHLERS ,  Michael Bertil Einar SARNING ,  Robert Kristoffer BERG ,  Hendrik VAN DAM

IPC: C07D233/34 ,  C07C209/78

Abstract: Urea derivatives, methods for preparing ethylene amines, and methods of polymer manufacturing are provided. An exemplary method for preparing ethylene amines with n ethylene units and n+1 amine groups wherein n is at least 4, or urea derivatives of said ethylene amines, includes reacting an ethanolamine-functional compound, an amine-functional compound, and a carbon oxide delivering agent, wherein the ethanolamine-functional compound is of the formula HO—(C2H4—NH—)qH, q is at least 1, the amine-functional compound is of the formula H2N—(C2H4—NH—)rH, r is at least 1, the sum q+r is at least 4 and wherein optionally one or more of the ethanol-amine functional compound or amine-functional compound are at least partly used as their cyclic carbamate derivative, or linear or cyclic urea derivative.

公开(公告)号：US09527811B2

公开(公告)日：2016-12-27

申请号：US14570996

申请日：2014-12-15

Applicant: AbbVie Deutschland GmbH & Co. KG ,  AbbVie Inc.

Inventor： Helmut Mack ,  Andreas Kling ,  Katja Jantos ,  Achim Moeller ,  Wilfried Hornberger ,  Charles W. Hutchins

IPC: C07D207/26 ,  C07D207/28 ,  C07D401/12 ,  C07D233/34 ,  C07D239/10 ,  C07D207/22 ,  C07D211/78 ,  C07D211/76 ,  C07D233/32 ,  C07D275/03 ,  C07D401/06 ,  C07D405/12 ,  C07D409/12 ,  C07D417/12 ,  C07D213/81

CPC classification number: C07D207/22 ,  C07D207/26 ,  C07D207/28 ,  C07D211/76 ,  C07D211/78 ,  C07D213/81 ,  C07D233/32 ,  C07D233/34 ,  C07D239/10 ,  C07D275/03 ,  C07D401/06 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  C07D417/12

Abstract: The present invention relates to novel carboxamide compounds and their use for the manufacture of a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also relates to the use of these carboxamide compounds for treating a disorder associated with an elevated calpain activity.The carboxamide compounds are compounds of the general formula I in which R1, R2, R3a, R3b, R4, Q, Y, A and X have the meanings mentioned in the claims and the description, the tautomers thereof and the pharmaceutically suitable salts thereof. In particular, the compounds have the general formula Ia and Ib in which R1, r, R2b, R3a, R3b, R4, Y and X have the meanings mentioned in the claims, including the tautomers thereof and the pharmaceutically suitable salts thereof. Of these compounds those are preferred wherein Y is a moiety CH2—CH2, CH2—CH2—CH2, N(Ry#)—CH2, N(Ry#)—CH2—CH2 or CH═CH—CH═, each optionally having 1 or 2H-atoms replaced with identical or different radicals Ry, wherein Ry and Ry# have the meanings mentioned in the claims.

公开(公告)号：US09440928B2

公开(公告)日：2016-09-13

申请号：US14233307

申请日：2012-07-19

Applicant: Ram Gupta ,  Irina Kobylanska ,  Urvee Treasurer ,  Lawrence Flood

Inventor： Ram Gupta ,  Irina Kobylanska ,  Urvee Treasurer ,  Lawrence Flood

IPC: C07D233/34 ,  C07D233/36 ,  C07D233/32

CPC classification number: C07D233/36 ,  C07D233/32 ,  C07D233/34

Abstract: The invention relates to a process for the synthesis of N-substituted cyclic alkylene ureas by reacting a multifunctional aliphatic amine A having at least two amino groups which may be primary or secondary, at least one of which is a primary amino group, —NH2, and at least one of which is a secondary amino group, >NH, the other hydrogen group whereof having been substituted by a hydrocarbyl group which in turn may be substituted by a hydroxyl group, or an amino group, or a carboxyl group, or a ketone carbonyl group, or a hydrazide or hydrazone group, or a mercaptan group, and at least one further functional group selected from the group consisting of primary or secondary amino groups and hydroxyl groups, and an aliphatic organic carbonate component C selected from the group consisting of dialkyl carbonates CD and of alkylene carbonates CA.

Abstract translation: 本发明涉及一种合成N-取代的环状亚烷基脲的方法，该方法是使具有至少两个可以是伯或仲的氨基的多官能脂族胺A，其中至少一个是伯氨基，-NH 2， 并且其中至少一个是仲氨基，NH，另一个氢基团被烃基取代，烃基又可以被羟基，氨基或羧基取代，或 酮羰基或酰肼或腙基或硫醇基，以及至少一种选自伯或仲氨基和羟基的另外的官能团，和选自以下的脂族有机碳酸酯组分C： 的碳酸二烷基酯CD和碳酸亚烷基酯CA。

公开(公告)号：US09079852B2

公开(公告)日：2015-07-14

申请号：US13862647

申请日：2013-04-15

Applicant: Dennis C. Liotta ,  James P. Snyder ,  Stephen F. Traynelis ,  Lawrence Wilson ,  Cara Mosley ,  Raymond J. Dingledine ,  Scott Myers ,  Yesim Altas Tahirovic

Inventor： Dennis C. Liotta ,  James P. Snyder ,  Stephen F. Traynelis ,  Lawrence Wilson ,  Cara Mosley ,  Raymond J. Dingledine ,  Scott Myers ,  Yesim Altas Tahirovic

IPC: A61K31/421 ,  A61K31/4166 ,  A61K31/495 ,  C07D241/04 ,  C07D263/18 ,  C07D233/08 ,  C07D209/34 ,  C07C217/20 ,  C07C235/20 ,  C07C311/08 ,  C07D215/227 ,  C07D233/34 ,  C07D235/26 ,  C07D263/58 ,  C07D295/088 ,  C07D211/52 ,  C07D213/74 ,  C07D233/32

CPC classification number: C07D209/34 ,  C07C217/20 ,  C07C235/20 ,  C07C311/08 ,  C07D211/52 ,  C07D213/74 ,  C07D215/227 ,  C07D233/32 ,  C07D233/34 ,  C07D235/26 ,  C07D263/58 ,  C07D295/088

Abstract: Provided are compounds, pharmaceutical compositions and methods of treatment or prophylaxis of disorders associated with NMDA receptor activity, including neuropathic pain, stroke, traumatic brain injury, epilepsy, and related neurologic events or neurodegeneration. Compounds are of the general Formula I, or a pharmaceutically acceptable salt, ester, prodrug or derivative thereof are provided: wherein: each (L)k-Ar1 is a substituted or unsubstituted, mono or bicyclic aryl or heteroaryl; W is a bond, alkyl, or alkenyl; X is a bond, NR1 or O and each R1 and R2 is independently H, alkyl, alkenyl or aralkyl or R1 and R2 taken together form a 5-8 membered ring; R3−-R6 are selected from certain specific substituents or a carbonyl; Y is a bond, O, S, SO, SO2, CH2, NH, N(alkyl), or NHC(═O); and Z is OH, NR6R7, NR8SO2(alkyl), NR8C(O)NR6R7, NR8C(O)O(alkyl), NR8-dihydrothiazole, or NR8-dihydroimidazole or wherein Z can fuse with Ar2 to form selected heterocycles.

Abstract translation: 提供了治疗或预防与NMDA受体活性相关的病症的化合物，药物组合物和方法，包括神经性疼痛，中风，创伤性脑损伤，癫痫以及相关的神经系统事件或神经变性。 化合物为通式I，或其药学上可接受的盐，酯，前药或衍生物：其中：（L）k-Ar1为取代或未取代的单或双环芳基或杂芳基; W是键，烷基或烯基; X是键，NR 1或O，并且每个R 1和R 2独立地是H，烷基，烯基或芳烷基，或者R 1和R 2一起形成5-8元环; R 3 -R 6选自某些具体取代基或羰基; Y是键，O，S，SO，SO 2，CH 2，NH，N（烷基）或NHC（= O）; 并且Z是OH，NR 6 R 7，NR 8 SO 2（烷基），NR 8 C（O）NR 6 R 7，NR 8 C（O）O（烷基），NR 8 - 二氢噻唑或NR 8 - 二氢咪唑，或其中Z可与Ar 2融合形成选定的杂环。

公开(公告)号：US08853215B2

公开(公告)日：2014-10-07

申请号：US13264510

申请日：2010-04-16

Applicant: Shizuo Kasai ,  Kevin Francis McGee, Jr.

Inventor： Shizuo Kasai ,  Kevin Francis McGee, Jr.

IPC: A61K31/495 ,  C07D295/00 ,  C07D207/416 ,  C07D335/02 ,  C07D231/18 ,  C07D295/215 ,  C07D261/18 ,  C07D209/24 ,  C07D209/18 ,  C07D295/185 ,  C07D213/75 ,  C07D211/88 ,  C07D263/34 ,  C07D513/04 ,  C07D213/70 ,  C07D213/65 ,  C07D235/28 ,  C07D233/72 ,  C07D233/64 ,  C07D307/24 ,  C07D211/76 ,  C07D231/14 ,  C07D211/58 ,  C07D233/90 ,  C07D257/04 ,  C07D211/46 ,  C07D213/61 ,  C07D261/12 ,  C07D209/42 ,  C07D207/16 ,  C07D211/22 ,  C07D307/30 ,  C07D233/34 ,  C07D309/38 ,  C07D249/10 ,  C07D211/34 ,  C07D213/81 ,  C07D207/26

CPC classification number: C07D295/185 ,  C07D207/16 ,  C07D207/26 ,  C07D207/416 ,  C07D209/18 ,  C07D209/24 ,  C07D209/42 ,  C07D211/22 ,  C07D211/34 ,  C07D211/46 ,  C07D211/58 ,  C07D211/76 ,  C07D211/88 ,  C07D213/61 ,  C07D213/65 ,  C07D213/70 ,  C07D213/75 ,  C07D213/81 ,  C07D231/14 ,  C07D231/18 ,  C07D233/34 ,  C07D233/64 ,  C07D233/72 ,  C07D233/90 ,  C07D235/28 ,  C07D249/10 ,  C07D257/04 ,  C07D261/12 ,  C07D261/18 ,  C07D263/34 ,  C07D295/215 ,  C07D307/24 ,  C07D307/30 ,  C07D309/38 ,  C07D335/02 ,  C07D513/04

Abstract: The present invention relates to a compound represented by the formula wherein each symbol is as defined in the present specification, which has a superior RBP4-lowering action and is useful as a pharmaceutical composition for the prophylaxis or treatment of a disease or condition mediated by an increase in RBP4.

Abstract translation: 本发明涉及由下式表示的化合物，其中每个符号如本说明书中所定义，其具有优异的RBP4降低作用，并且可用作预防或治疗由下列疾病介导的疾病或病症的药物组合物： 增加RBP4。

公开(公告)号：US20130197237A1

公开(公告)日：2013-08-01

申请号：US13809795

申请日：2011-07-12

Applicant: Nicolas Seeboth ,  Serguey Ivanov ,  Jean-Luc Couturier ,  Manuel Hidalgoo

Inventor： Nicolas Seeboth ,  Serguey Ivanov ,  Jean-Luc Couturier ,  Manuel Hidalgoo

IPC: C07D233/34 ,  C07D233/36

CPC classification number: C07D233/34 ,  C07D233/36

Abstract: The present invention relates to nitrogenous associative molecules comprising at least one unit rendering them capable of associating with one another or with a filler, via noncovalent bonds, and comprising a function capable of reacting with a polymer containing unsaturations so as to form a covalent bond with said polymer.

Abstract translation: 本发明涉及包含至少一个单元的含氮缔合分子，使得它们能够通过非共价键彼此缔合或与填料缔合，并且包含能够与含有不饱和键的聚合物反应以便与 所述聚合物。

公开(公告)号：US20120309777A1

公开(公告)日：2012-12-06

申请号：US13579534

申请日：2011-02-16

Applicant: René C. Gaudreault ,  Sébastien Fortin

Inventor： René C. Gaudreault ,  Sébastien Fortin

IPC: A61K31/4166 ,  A61K31/513 ,  A61K31/4709 ,  C07D403/12 ,  C07D401/12 ,  C07D233/34 ,  A61K31/4178 ,  C12N5/02 ,  C07D239/10

CPC classification number: C07D233/34 ,  C07D239/10 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12

Abstract: Compounds of formula (I): wherein R1, R2, R3, R4, R7, R6, R7, R8, R9, A, X and Y as defined herein are provided as useful for the treatment of cancer or for the manufacture of anti-cancer agents.

Abstract translation: 提供式（I）的化合物：其中本文定义的R1，R2，R3，R4，R7，R6，R7，R8，R9，A，X和Y可用于治疗癌症或用于制备抗 - 癌症药物。

公开(公告)号：US20050113373A1

公开(公告)日：2005-05-26

申请号：US10507708

申请日：2003-03-11

Applicant: Kristof Van Emelen ,  Janine Arts ,  Leo Backx ,  Hans De Winter ,  Sven Van Brandt ,  Marc Verdonck ,  Lieven Meerpoel ,  Isabelle Pilatte ,  Virginie Poncelet ,  Alexey Dyatkin

Inventor： Kristof Van Emelen ,  Janine Arts ,  Leo Backx ,  Hans De Winter ,  Sven Van Brandt ,  Marc Verdonck ,  Lieven Meerpoel ,  Isabelle Pilatte ,  Virginie Poncelet ,  Alexey Dyatkin

IPC: C07D249/12 ,  A61K31/40 ,  A61K31/438 ,  A61K31/4427 ,  A61K31/445 ,  A61K31/4545 ,  A61K31/472 ,  A61K31/495 ,  A61K31/496 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K31/517 ,  A61K31/52 ,  A61K31/53 ,  A61K31/5377 ,  A61K31/55 ,  A61K31/551 ,  A61K45/00 ,  A61P1/04 ,  A61P3/10 ,  A61P5/00 ,  A61P9/00 ,  A61P9/02 ,  A61P9/08 ,  A61P9/10 ,  A61P11/00 ,  A61P11/02 ,  A61P11/06 ,  A61P13/08 ,  A61P13/10 ,  A61P13/12 ,  A61P15/00 ,  A61P17/00 ,  A61P17/04 ,  A61P17/06 ,  A61P17/10 ,  A61P17/14 ,  A61P17/16 ,  A61P19/02 ,  A61P19/06 ,  A61P21/04 ,  A61P25/00 ,  A61P25/16 ,  A61P25/28 ,  A61P27/02 ,  A61P27/06 ,  A61P29/00 ,  A61P31/18 ,  A61P35/00 ,  A61P35/02 ,  A61P37/02 ,  A61P37/04 ,  A61P37/06 ,  A61P37/08 ,  A61P43/00 ,  C07D20060101 ,  C07D207/09 ,  C07D207/14 ,  C07D207/28 ,  C07D211/26 ,  C07D211/58 ,  C07D213/74 ,  C07D213/78 ,  C07D213/82 ,  C07D215/36 ,  C07D217/02 ,  C07D217/04 ,  C07D233/34 ,  C07D233/64 ,  C07D233/84 ,  C07D233/90 ,  C07D237/24 ,  C07D239/42 ,  C07D239/48 ,  C07D241/04 ,  C07D241/24 ,  C07D241/26 ,  C07D243/08 ,  C07D261/10 ,  C07D295/14 ,  C07D295/155 ,  C07D295/20 ,  C07D295/22 ,  C07D295/26 ,  C07D307/68 ,  C07D307/79 ,  C07D317/58 ,  C07D333/34 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/04 ,  C07D409/12 ,  C07D409/14 ,  C07D413/02 ,  C07D413/04 ,  C07D413/12 ,  C07D471/10 ,  C07D487/08 ,  C07D513/04 ,  C12Q1/48 ,  C07D41/02 ,  C07D43/02

CPC classification number: C07D413/12 ,  A61K31/40 ,  A61K31/402 ,  A61K31/435 ,  A61K31/4427 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/472 ,  A61K31/495 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  A61K45/06 ,  C07D207/09 ,  C07D207/14 ,  C07D207/277 ,  C07D207/28 ,  C07D211/14 ,  C07D211/58 ,  C07D213/78 ,  C07D213/81 ,  C07D213/82 ,  C07D217/02 ,  C07D217/04 ,  C07D217/16 ,  C07D233/90 ,  C07D239/42 ,  C07D241/04 ,  C07D241/24 ,  C07D243/08 ,  C07D261/10 ,  C07D295/155 ,  C07D295/22 ,  C07D295/26 ,  C07D307/68 ,  C07D307/79 ,  C07D333/34 ,  C07D401/04 ,  C07D401/12 ,  C07D403/04 ,  C07D403/12 ,  C07D405/06 ,  C07D409/04 ,  C07D409/12 ,  C07D409/14 ,  C07D413/04 ,  C07D413/14 ,  C07D471/04 ,  C07D471/10 ,  C07D513/04 ,  C12Q1/34 ,  C12Q1/48 ,  G01N33/573 ,  G01N2333/91

Abstract: This invention comprises the novel compounds of formula (I) wherein n, m, t, R1, R2, R3, R4, L, Q, X, Y, Z and have defined meanings, having histone deacetylase inhibiting enzymatic activity; their preparation, compositions containing them and their use as a medicine.

Abstract translation: 本发明包括新的式（I）化合物，其中n，m，t，R 1，R 2，R 3，R 3， 具有组氨酸脱乙酰酶抑制酶活性的含义; 其制剂，含有它们的组合物及其作为药物的用途。